Industri

Wellstar Kennestone Opens 9-Story Tower, Expand Special...

Wellstar Kennestone Regional Medical Center in Marietta, Ga., recently opened a ...

FUJIFILM opens new iPSC facility in Madison, US

The site is anticipated to expand the company’s production capacity for iPSC-bas...

BMS and Anthropic collaborate for Claude implementation

The initiative will embed agentic capabilities throughout BMS’ research, clinica...

Shaily announces approval, launch of customer combo pro...

USFDA Tentative Approval, Health Canada Notice of Compliance, and India CDSCO a...

SERB signs agreement to acquire Idefirix rights for $13...

The deal covers the European Union, Iceland, Liechtenstein, Norway, Switzerland,...

QIAGEN and NVIDIA partner on AI drug discovery

The move aims to allow pharmaceutical and biotechnology researchers to use AI mo...

Beyond scale: Rethinking new frontiers in building exce...

Hyderabad played host to a room full of hard questions as Express Pharma brough...

The cosmetic-medicine grey zone

Prof Dr Debraj Shome, Clinical Scientist and Research Mentor, QR678 opines that...

MSME Pharma firms warn of rising compliance burden as r...

India’s MSME pharmaceutical manufacturers are facing mounting financial and ope...

Dr. Reddy’s Laboratories launches oral semaglutide bios...

Dr. Reddy’s Laboratories, a global pharmaceutical company, announced the launch...

Tariffs & sustainability: Why Indian pharma can no long...

For a long time, Indian pharmaceutical companies could treat trade policy as a ...

India is well on its path to strongly push back the per...

As we mark International Clinical Trial Day today, Dr Seema Pai, President, ISC...

Next Generation Dovetail Deck and Pintail Anchors

Vulcraft-Verco developed the PinTail™ Anchor: a robust hanging solution designed...

HAB Pharma completes strategic merger with Signature Ph...

HAB Pharma and Signature Phytochemicals have completed a strategic merger throu...

VERTANICAL’s VER-01 gains FDA breakthrough status for l...

The designation follows two randomised, controlled Phase III trials that showed ...

Regeneron signs $2.32bn deal with Parabilis for Helicon...

Helicons are stabilised, cell-penetrant alpha-helical peptides engineered to int...